NMD Pharma (@NMDPharma) / Twitter
NMD Pharma Archives - Pharmtech Focus
NMD Pharma Lights Up INCUBA/Skejby - Rare Disease Day 2023
NMD Pharma A/S | LinkedIn
NMD Pharma is about to start a combined Phase I/IIa clinical trial with its ClC-1 channel inhibitor in healthy subjects and patients with myasthenia gravis – ION CHANNEL LIBRARY
Thomas H. Pedersen - CEO at NMD Pharma | The Org
NMD Pharma
Jeito Capital Becomes Key Investor in NMD Pharma as Part of a €35 Million New Financing | Business Wire
NMD PHARMA APS innovation strategy - GoodIP
NMD pulls in $40M from Jeito-led, Roche-backed syndicate, gaining financial muscle to crack myasthenia gravis market | Fierce Biotech
Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service
NMD Pharma A/S | LinkedIn
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma Raises $39.7 Million to Advance Pipeline Targeting Rare Neuromuscular Disorders - Global Genes
NMD Pharma
NMD Pharma Nears Validation For ClC-1 Inhibition With Lead Program In Myasthenia Gravis :: Scrip
NMD Pharma gets green light to proceed with neuromuscular target — MedWatch
Chasing Big Pharma rivals, NMD posts data on rare disease drug
NMD Pharma
NMD Pharma A/S | LinkedIn
NMD Pharma (@NMDPharma) / Twitter
NMD Pharma raises €35m to expand pipeline - European Pharmaceutical Manufacturer
NMD Pharma A/S | LinkedIn
NMD Pharma
